A new publication referencing pramlintide was released on September 11, 2026. The paper is titled "Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes." The journal name was not specified in the available event data.
Pramlintide remains an approved compound. This publication entry documents its inclusion in a broader review of non-insulin pharmacological agents used in type 2 diabetes management. No specific findings, results, or conclusions from the publication were included in the available event data.
This entry serves as a record that the publication exists and references pramlintide within its scope. No efficacy, safety, or outcome data from the paper itself is included here, as that information was not provided in the event details.
Readers interested in learning more about how pramlintide is used and its regulatory background can refer to the compound overview for additional context.